New research in Diabetes Care suggests fetal overgrowth begins prior to gestational diabetes screenings, and the authors suggest screening women closer to 24 weeks than 28 weeks. The study found women who developed gestational diabetes were almost five times more likely to have greater fetal abdominal circumference and nearly three times as likely to have a lower fetal head circumference to abdominal circumference ratio at 28 weeks, but at 20 weeks, there was no association between the measurements and gestational diabetes risk.
Both glycated hemoglobin (HbA1C) and oral glucose tolerance test are useful for identifying adolescents with polycystic ovary syndrome with dysglycemia and may identify different populations of girls at risk for long-term cardiometabolic consequences. (Full-text access is time limited.)
Patients with long-term type 1 diabetes assigned to four different groups, with some performing multiple daily injections and self-monitoring of blood glucose and others using continuous subcutaneous insulin infusion pumps, all attained significant improvements in hypoglycemia awareness at 24 weeks, a study indicated. However, those who used continuous subcutaneous insulin infusion pumps reported greater treatment satisfaction compared with the injection group, researchers wrote in Diabetes Care.
Zydus Group obtained federal approval to commence early-stage trials for its orally active, small-molecule new chemical entity designed to treat diabetes using weekly doses. The compound, called ZYDPLA1, belongs to the gliptin class of diabetes drugs.
A small study revealed that fetal thigh measurement at 28 weeks of gestation can predict babies' likelihood of adiposity at birth. Researchers noted that prepregnancy body mass index, maternal weight gain, birth weight were not associated with neonatal adiposity, nor were fetal abdominal circumference and estimated weight. The findings were presented at the Society of Gynecologic Investigation meeting.